Zalviso

RSS

Withdrawn

This medicine's authorisation has been withdrawn

sufentanil
MedicineHumanWithdrawn

Polish is available via eTranslation, the European Commission's machine translation service.

Translate to Polish | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 5 August 2022, the European Commission withdrew the marketing authorisation for Zalviso (sufentanil) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, FGK Representative Service GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Zalviso was granted marketing authorisation in the EU on 18 September 2015 for the management of acute moderate to severe post-operative pain. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2020. 

The European Public Assessment Report (EPAR) for Zalviso is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (760.64 KB - PDF)

Zobacz

español (ES) (667.71 KB - PDF)

Zobacz

čeština (CS) (739.15 KB - PDF)

Zobacz

dansk (DA) (665.9 KB - PDF)

Zobacz

Deutsch (DE) (670.41 KB - PDF)

Zobacz

eesti (ET) (665.35 KB - PDF)

Zobacz

ελληνικά (EL) (762.93 KB - PDF)

Zobacz

français (FR) (669.36 KB - PDF)

Zobacz

hrvatski (HR) (686.42 KB - PDF)

Zobacz

italiano (IT) (666.44 KB - PDF)

Zobacz

latviešu (LV) (738.28 KB - PDF)

Zobacz

lietuvių (LT) (688.61 KB - PDF)

Zobacz

magyar (HU) (733.2 KB - PDF)

Zobacz

Malti (MT) (741.01 KB - PDF)

Zobacz

Nederlands (NL) (667.09 KB - PDF)

Zobacz

polski (PL) (738.41 KB - PDF)

Zobacz

português (PT) (668.03 KB - PDF)

Zobacz

română (RO) (688.79 KB - PDF)

Zobacz

slovenčina (SK) (737.52 KB - PDF)

Zobacz

slovenščina (SL) (730.65 KB - PDF)

Zobacz

suomi (FI) (665.44 KB - PDF)

Zobacz

svenska (SV) (667.37 KB - PDF)

Zobacz

Product information

български (BG) (2.02 MB - PDF)

Zobacz

español (ES) (1.14 MB - PDF)

Zobacz

čeština (CS) (1.73 MB - PDF)

Zobacz

dansk (DA) (1.14 MB - PDF)

Zobacz

Deutsch (DE) (1.08 MB - PDF)

Zobacz

eesti (ET) (1.15 MB - PDF)

Zobacz

ελληνικά (EL) (2.07 MB - PDF)

Zobacz

français (FR) (1.17 MB - PDF)

Zobacz

hrvatski (HR) (1.23 MB - PDF)

Zobacz

italiano (IT) (1.08 MB - PDF)

Zobacz

latviešu (LV) (3.17 MB - PDF)

Zobacz

lietuvių (LT) (1.21 MB - PDF)

Zobacz

magyar (HU) (1.8 MB - PDF)

Zobacz

Malti (MT) (1.81 MB - PDF)

Zobacz

Nederlands (NL) (1.13 MB - PDF)

Zobacz

polski (PL) (1.77 MB - PDF)

Zobacz

português (PT) (1.14 MB - PDF)

Zobacz

română (RO) (1.24 MB - PDF)

Zobacz

slovenčina (SK) (1.72 MB - PDF)

Zobacz

slovenščina (SL) (1.74 MB - PDF)

Zobacz

suomi (FI) (1.05 MB - PDF)

Zobacz

svenska (SV) (1.14 MB - PDF)

Zobacz

Íslenska (IS) (1.11 MB - PDF)

Zobacz

norsk (NO) (1.14 MB - PDF)

Zobacz
Latest procedure affecting product information:T/0017
05/08/2022
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (630.83 KB - PDF)

Zobacz

español (ES) (589.36 KB - PDF)

Zobacz

čeština (CS) (612.66 KB - PDF)

Zobacz

dansk (DA) (588.95 KB - PDF)

Zobacz

Deutsch (DE) (588.89 KB - PDF)

Zobacz

eesti (ET) (588.92 KB - PDF)

Zobacz

ελληνικά (EL) (629.13 KB - PDF)

Zobacz

français (FR) (589.08 KB - PDF)

Zobacz

hrvatski (HR) (600.21 KB - PDF)

Zobacz

italiano (IT) (589.31 KB - PDF)

Zobacz

latviešu (LV) (622.41 KB - PDF)

Zobacz

lietuvių (LT) (605.38 KB - PDF)

Zobacz

magyar (HU) (618.12 KB - PDF)

Zobacz

Malti (MT) (620.25 KB - PDF)

Zobacz

Nederlands (NL) (589.22 KB - PDF)

Zobacz

polski (PL) (620.57 KB - PDF)

Zobacz

português (PT) (589.37 KB - PDF)

Zobacz

română (RO) (606.42 KB - PDF)

Zobacz

slovenčina (SK) (619.68 KB - PDF)

Zobacz

slovenščina (SL) (618.15 KB - PDF)

Zobacz

suomi (FI) (589.19 KB - PDF)

Zobacz

svenska (SV) (589.02 KB - PDF)

Zobacz

Íslenska (IS) (588.96 KB - PDF)

Zobacz

norsk (NO) (589.15 KB - PDF)

Zobacz

Product details

Name of medicine
Zalviso
Active substance
sufentanil
International non-proprietary name (INN) or common name
sufentanil
Therapeutic area (MeSH)
Pain, Postoperative
Anatomical therapeutic chemical (ATC) code
N01AH03

Pharmacotherapeutic group

Anesthetics

Therapeutic indication

Zalviso is indicated for the management of acute moderate to severe post-operative pain in adult patients.

Authorisation details

EMA product number
EMEA/H/C/002784
Marketing authorisation holder
FGK Representative Service GmbH

Heimeranstrasse 35
80338 Munich
Germany

Opinion adopted
23/07/2015
Marketing authorisation issued
18/09/2015
Revision
7

Assessment history

This page was last updated on

Share this page